I Squared Capital Appoints Philippe Lenoble and Bogdan Ciobotaru as Managing Directors
I Squared Capital, a leading independent global infrastructure investment firm, today announced two senior appointments to its investment and asset management teams in London.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250306212222/en/
Philippe Lenoble, Managing Director, I Squared (Photo: Business Wire)
Philippe Lenoble will join the investment team as Managing Director, reporting to Mohamed El Gazzar, Senior Partner. Bogdan Ciobotaru will join the asset management team as Managing Director reporting to Maxime Jacqz, Managing Director, who leads asset management in Europe.
The demands for new and improved infrastructure requires investors to balance the increasing opportunities with the right resourcing to manage the increased scale and complexity. I Squared is committed to expanding its investment and asset management capabilities in a thoughtful and deliberate way to seize this opportunity and deliver value for its partners across the globe. Europe continues to be an important market for us and Philippe and Bogdan’s experience, and expertise will support our ambitions for the region during this pivotal period for infrastructure.
Philippe brings nearly 30 years of investment industry experience from across the infrastructure sector. He is well known to the I Squared team having worked with us in one way or another for the last 15 years, most recently as an Operating Advisor and member of the Board of Directors of Arriva. Philippe previously spent 16 years at Goldman Sachs where he was a Managing Director of the GS Infrastructure Funds. He has also held leadership roles at the Canadian pension fund, CDPQ, and Australian pension fund, AustralianSuper.
Bogdan brings 25 years of experience across investment banking, private equity and asset management in the infrastructure, telecoms and financial services sectors, initially at Morgan Stanley and subsequently at Renaissance Capital. Like Philippe, Bogdan also joined I Squared as an Operating Director but quickly demonstrated his value as Chair of Ezee Fiber and on the boards of Exa Infrastructure, Cube Cold and, most recently, Arriva.
“Philippe and Bogdan have quickly proven themselves to be valuable partners to our investment teams and thoughtful and impactful contributors to our portfolio companies,” said Mohamed El Gazzar, Senior Partner, I Squared Capital. “These appointments reflect our commitment to strengthening our investment team as we seek to capitalize on the opportunity set we see and our pursuit of high-quality infrastructure opportunities globally.”
These appointments follow that of Ben Harper as Managing Director, Head of Sustainability earlier this week and reflect I Squared’s continued efforts to strengthen its investment and value creation capabilities.
Philippe holds a master’s degree in engineering and finance from Université Catholique de Louvain (Belgium) and the CFA designation. He is an active member of the investment community and serves on the Board of CFA UK, the professional body representing approximately 12,000 investment professionals in the UK.
Bogdan holds a bachelor’s degree from the Academy of Economic Studies in Romania and an MBA from Oxford University.
About I Squared Capital
I Squared is a leading independent global infrastructure investor with over $40 billion in assets under management. We are known for the development of investment platforms in infrastructure projects where we start small and grow big. We use global insights and deep local intelligence to solve complex problems, foster smarter businesses, serve local communities, and invest in a more sustainable future to provide essential services to millions of people around the world. We are a team of over 280 people, headquartered in Miami with offices in Abu Dhabi, London, Munich, New Delhi, São Paulo, Singapore, Sydney and Taipei. We operate a diverse portfolio of 89 companies in more than 70 countries with over 66,000 employees in a variety of sectors including utilities, energy, digital infrastructure, transport, environmental infrastructure, and social infrastructure. You can find out more by visiting: www.isquaredcapital.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250306212222/en/
Contacts
For media inquiries, please contact:
Dominic McMullan / Shelly Hagan
info@isquaredcapital.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
LEO Pharma Presents New Late-Breaking Delgocitinib Cream Data For the Third Consecutive Year at AAD 20258.3.2025 17:00:00 EET | Press release
LEO Pharma A/S, a global leader in medical dermatology, today presented late-breaking data showcasing responses in a subgroup of patients from the DELTA 1 and 2 trials at the 83rd American Academy of Dermatology (AAD) 2025 Annual Meeting.1 The presentation marks the third consecutive year that LEO Pharma has presented late-breaking data at AAD. Alongside this presentation, new systemic exposure data has also been shared for delgocitinib cream at the meeting.2 “The data unveiled today further contributes to LEO Pharma’s ever-growing body of scientific evidence for the treatment of moderate to severe CHE,” said Christophe Bourdon, Chief Executive Officer, LEO Pharma. “Our research and work in CHE is a testament to our ambition to maintain the broadest global product portfolio in dermatology, and I am proud we can share this latest analysis from our pivotal DELTA trials.” Delgocitinib cream is currently under investigation in the United States. Late-Breaking Post Hoc Data Analysis The sub
Incyte Announces Results of Phase 3 Clinical Trials Evaluating Ruxolitinib Cream 1.5% (Opzelura ® ) in Patients with Prurigo Nodularis (PN) at 2025 American Academy of Dermatology Annual Meeting8.3.2025 16:01:00 EET | Press release
Incyte (Nasdaq:INCY) today announced results from its pivotal Phase 3 TRuE-PN clinical trial program –TRuE-PN1 and TRuE-PN2 studies – evaluating the safety and efficacy of twice-daily ruxolitinib cream 1.5% (Opzelura®), a topical JAK1/2 inhibitor, in adult patients (≥18 years) with prurigo nodularis (PN). The positive TRuE-PN1 data were presented as a late-breaking oral presentation (Session: S028 – Late-Breaking Research: Session 1) today at the 2025 American Academy of Dermatology (AAD) Annual Meeting, being held March 7–11, 2025, in Orlando. The TRuE-PN1 study met its primary endpoint demonstrating that significantly more PN patients who applied ruxolitinib cream 1.5% versus vehicle control achieved a ≥4-point improvement from baseline in Worst-Itch Numeric Rating Scale (WI-NRS4) at Week 12 (44.6% vs 20.6%; P=0.0003). Significant itch improvements were observed with ruxolitinib cream 1.5% versus vehicle control at Day 7 (22.4% vs 8.0%; P=0.0064), with numerical improvements versus v
Proteintech Unveils Next-Gen 3D Epitope Mapping to Accelerate Life Science Research7.3.2025 21:16:00 EET | Press release
Proteintech, a global leader in antibodies and life science solutions, is excited to announce additional product characterization for primary antibody targets on its website (ptglab.com). The advanced validation data, 3D Epitope Mapping, is designed to enhance the efficiency and accuracy of antibody-related selection, empowering scientists with the data they need to advance their work, from basic research to the design of novel therapeutics. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250307777605/en/ On the Proteintech website (ptglab.com), researchers can explore antibody binding sites with the new interactive 3D epitope viewer. (Photo: Business Wire) The 3D Epitope Mapping is a state-of-the-art solution that utilizes a combination of experimental techniques, including peptide scanning and microbial display, aiming to precisely map the antibody binding site (epitope) on a target protein. This mapping is then visualized
Vertex Announces UK MHRA Approval of ALYFTREK ® (Deutivacaftor/Tezacaftor/Vanzacaftor), a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis7.3.2025 17:02:00 EET | Press release
Vertex Pharmaceuticals (Nasdaq: VRTX) announced today that the United Kingdom (UK) Medicines and Healthcare products Regulatory Agency (MHRA) has granted approval for ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor),a once-daily next-in-class triple combination cystic fibrosis transmembrane conductance regulator (CFTR) modulator treatment for people living with cystic fibrosis (CF) ages 6 years and older who have at least one F508del mutation or another responsive mutation in the CFTR gene. “For more than 20 years we have been focused on discovering medicines that treat the underlying cause of the disease with the goal of helping people live longer and better lives. The approval of ALYFTREK, our fifth CFTR modulator regimen, represents another significant milestone in that journey for people with CF in the UK,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer at Vertex. “The deutivacaftor/tezacaftor/vanzacafto
Interactive Brokers Nominates Lori Conkling to its Board of Directors7.3.2025 17:00:00 EET | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global electronic broker, announced the nomination of Lori Conkling as an independent director of the firm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250307601860/en/ Lori Conkling (Photo: Business Wire) Ms. Conkling will bring a wealth of knowledge to Interactive Brokers. As Head of TV & Film Licensing at Netflix, she oversees content acquisition and business development for their ad-free and ad-supported platforms. Before joining Netflix, she held leadership positions at Google, including Global Head of TV, Film and Sports for YouTube and YouTube TV. “We are pleased to nominate Lori to the Board of Directors and look forward to leveraging her expertise to enhance our profile across the media landscape,” said Thomas Peterffy, Founder and Chairman of Interactive Brokers. “A successful senior executive with over 25 years of experience in the media space, Ms. Conkling will
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom